Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience

Anwer Nusliha1, Ushantha Dalpatadu1, Binara Amarasinghe1, Pramodh Chitralsinghe2 and Kemal Ismail Deen2*

Abstract

Background: Familial Adenomatous Polyposis (FAP) is an autosomal dominant condition giving rise to multiple adenomatous polyps in the colon which invariably become malignant by the fourth decade. Congenital hypertrophy of retinal pigment epithelium (CHRPE) is one of its extra intestinal manifestations early in childhood seen, present in 90% of FAP population and is easy to detect.

Findings: Patients diagnosed with FAP and at risk first degree family members were screened for CHRPE using a slit lamp and indirect ophthalmoscopy. The retina of 17 diagnosed FAP patients and 13 individuals at risk were examined. The site and size of CHRPE lesions were documented. Thirteen (76%) of 17 FAP patients (male-10, female-7, median age - 30 years; range 15-55 years) had CHRPE lesions; seven (54%) had bilateral CHRPE lesions and six (46%) had unilateral lesions. A single lesion was detected in 6 (46%) while 7 (54%) patients had multiple lesions. Of 13 at risk individuals (7- male, female-6; median age 34; range 16-52 years), one was positive for CHRPE and 12 were free of retinal lesions. The sensitivity of the presence of a CHRPE lesion in association with colonic polyps in FAP was 76%, specificity 92%, positive predictive value 93%, and negative predictive value 75%.

Conclusions: This study found a high sensitivity and specificity for a CHRPE lesion to be associated with colonic polyps of FAP and hence a useful screening method in a burdened health-care system. The method is minimally invasive and simple and would be of particular value in screening children at risk for FAP.

Keywords: Familial adenomatous polyposis coli, Retinal pigmentation, Ophthalmic screening

Background

Familial adenomatous polyposis (FAP) is a genetic disorder transmitted in an autosomal dominant pattern [1,2]. Patients develop multiple adenomatous polyps in the colon varying from a hundred to thousands in number. If left, these polyps will invariably transform, through the adenoma-carcinoma sequence, to colorectal malignancy [3-5]. Therefore early diagnosis and appropriate treatment is essential. Patients may develop extra intestinal manifestations such as congenital hypertrophy of retinal pigment epithelium (CHRPE), sebaceous cysts (51%), desmoids tumours (26%), and in lesser proportions, osteomas, lipomas (Gardner’s syndrome ) and extra intestinal malignancies; hepatomas, retinoblastomas and brain tumours (Turcot’s syndrome) [6-9]. FAP is also associated with the presence of polyps in the upper gastro intestinal tract in 90 to 100 percent [7,8]. Familial adenomatous polyposis is caused by mutations in the adenomatous polyposis coli (APC) gene, a tumour suppressor gene, located in the long arm of chromosome 5 [10-12]. The condition is autosomal dominant making half of the off spring of an affected individual parent at risk of developing FAP [10,11]. Disease has a hundred percent penetrance when the genotype is present. FAP related CHRPE may not be seen in all with the FAP genotype. For example, mutations in codon
Families with familial adenomatous polyposis (FAP) have a genetic mutation in the adenomatous polyposis coli (APC) gene, leading to excessive growth of benign and malignant colonic adenomas [1]. The APC gene is located on chromosome 5 at position 1597 [13]. Mutations in this gene lead to the formation of adenomatous polyps and have a significant impact on the individual's health. The APC gene is critical in regulating the cell cycle and preventing the formation of malignant tumors. The mutations result in the production of a truncated protein, which affects the normal function of the gene. The resultant truncated protein disrupts the normal cell cycle control, leading to an increased risk of developing colorectal cancer [14].

The APC gene is part of a complex genetic syndrome known as FAP, which is characterized by the presence of numerous adenomatous polyps in the colon and rectum. The syndrome is autosomal dominant, meaning that only one copy of the defective gene is needed to express the disease. This makes detection of CHRPE in asymptomatic individuals who are at risk an attractive screening option. It is one of the commonest and earliest extra colonic manifestations amongst FAP populations which may be present at birth (80%) or shortly after birth [8,15,16]. It is a darkly pigmented lesion with a depigmented halo in the retina [17]. It may be single or multiple, unilateral or bilateral. The size of a CHRPE lesion is variable but most are similar in diameter to the optic disc [20]. Lesions may be oval, round or bean shaped. Oval CHRPE lesions with fishtail shaped hypo-pigmented change at one or both ends may be associated with FAP [21].

Findings
Material and method
All individuals with a diagnosis of familial adenomatous polyposis made at the professorial surgical unit, Ragama between 1996 and 2010, were traced using clinical notes, endoscopic registers and admission books. Proformas were prepared for FAP patients and relatives at risk. The proforma contained all details about the patient including a plan of follow up. All FAP patients and individuals at risk were invited for registration in the FAP registry. A consent form was prepared in three languages (Sinhala, English and Tamil) and informed written consent was taken from all individuals participating in the activities of the registry. Those who consented were subjected to ophthalmological screening.

Ophthalmological examination was performed by an experienced ophthalmologist at North Colombo Teaching Hospital, Ragama. In all individuals, the eyes were checked for visual acuity as screening, followed by dilatation of the pupils using tropicamide and phenylephrine ophthalmic solution. After the pupils were fully dilated, slit lamp and indirect ophthalmoscopic examinations were performed to identify CHRPE lesions. If found, the site, size, number and shape of lesions were documented. A common side effect of this procedure was transient blurring of vision, which reversed in a few hours. Those who had ophthalmological screening for CHRPE lesions underwent a flexible sigmoidoscopy to look for the presence of polyps in the colon. If they were found to have polyps in the colon, an upper gastro intestinal endoscopy was also performed to look for polyps in the stomach and duodenum which may have malignant potential. Data were analyzed using the Statistical Package for Social Science version 17.0 (SPSS 17.0, Chicago, Illinois, USA). The sensitivity, specificity, positive predictive value and negative predictive value of CHRPE lesions in FAP and those at risk were calculated. Ethical clearance was obtained from the National Research Council, Sri Lanka and the Ethics Review Committee of University of Kelaniya medical school at Ragama.

Results
Seventeen diagnosed patients (male-10, female-7, median age- 30 years, range 15-55 years) with FAP and 13 individuals at risk (male-7, female-6, median age -34, range 16-52 years) were screened by an ophthalmologist. Of those with FAP, 13 (76%) were positive for CHRPE and 4 (24%) were negative. Six (46%) had a unilateral lesion and 7 (54%) had bilateral lesions. A solitary lesion in 6 (46%) and multiple lesions in the same eye were found in 7 (54%) patients. CHRPE lesions were either round or oval in shape. Of 13 individuals at risk, one had a single and large CHRPE lesion in one eye. Currently he does not have polyps in the colon and he is under surveillance for colonic and upper intestinal polyps. The remaining 12 were negative for both CHRPE in the retina and polyps in the colon. Response rate amongst affected individuals was 68% (17 out of 25 responded) and the at risk population was 32% (13 out of 40). The sensitivity of CHRPE as a screening test for the presence of FAP is 76% (95% CI : 0.56 - 0.97) and the specificity is 92% (95% CI: 0.78 - 1.07). The positive predictive value is 93% (95% CI: 0.79 - 1.06) while the negative predictive value is 75% (95% CI: 0.54 - 0.96).

Discussion
FAP is a genetic disorder which accounts for 1% of colorectal cancer [2,3,6]. Almost all patients develop colorectal cancer from adenomatous polyps unless detected early and managed by prophylactic removal of the colon and rectum. Therefore, early diagnosis is paramount. Currently the standard surgical treatment for FAP is restorative proctocolectomy with ileal pouch anal anastomosis. As CHRPE is one of the commonest and earliest extra intestinal manifestations, it lends itself as a screening tool for family members of FAP patients. The sensitivity of CHRPE in our study is 76% and it is comparable with other studies [17]. Chen CS et al reported 56% sensitivity in detecting FAP with CHRPE while none of the subjects with hereditary non polyposis colon cancer in
their study had retinal lesions [18]. All retinal lesions present in FAP patients may not be CHRPE. These may be harrmatomatous lesions which will be difficult to differentiate without special imaging techniques such as spectral-domain optical coherence tomography [24]. A drawback in our study was that ‘at risk’ individuals were assessed with endoscopy and not genetic studies. Some of these patients may have the genotype which is yet to manifest clinically. Although genetic testing is precise in most settings sigmoidoscopy is accepted as a screening tool due to financial constraints. We found that screening for CHRPE was relatively easy and caused minimum discomfort to the individual. Compared with colonoscopy, retinal screening seems more acceptable and less stigmatic. The examination is safe and repeatable. Although we did not study the cost benefit of retinal screening, it is our impression that retinal screening is less expensive compared with colonoscopy. Once CHRPE lesions are detected the screening of family members at risk could be intensified and should be done in a coordinated manner under the guidance of an FAP Registry. CHRPE detection can also help to persuade individuals at risk for regular follow up and improve their compliance. In Sri Lanka, financial constraints hinder genetic testing; screening for CHRPE will be most appropriate and invaluable to diagnose FAP. Furthermore, it may be suggested that CHRPE positivity will allow targeted genetic screening.

Conclusions
Screening for CHRPE is an easy, simple to perform, non invasive, safe and reproducible method of diagnosing FAP. As shown in this study it can be used as an effective first-line screening method for FAP. In conjunction with other screening methods it is invaluable in early diagnosis of FAP patients. As patients’ compliance is good with this screening method we could screen many patients who are at risk for FAP enabling early and appropriate management for those with FAP.

Abbreviations
CHRPE: Congenital hypertrophy of retinal pigment epithelium; FAP: Familial adenomatous polyposis coli.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AN, UD were involved in data collection, analysis and preparation of the manuscript. BA was involved in performing ophthalmic screening and critically appraising the manuscript. UD, PCC and KD were involved in patient management, data interpretation and appraising the manuscript. All authors read and approved the final manuscript.

Acknowledgement
The authors wish to thank DNU Jayathunga and D Pinto for their services in data collection analysis and coordination of the study. We declare that none of the authors received funding of what so ever from any organisation or individual for carrying out the research.

Author details
1North Colombo Teaching Hospital, Ragama, Sri Lanka. 2Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.

Received: 22 March 2014 Accepted: 10 October 2014
Published: 18 October 2014

References
1. Campbell WI, Spence RA, Parks TG: Familial adenomatous polyposis. BJ5 1994, 81:1722–1733.
2. Niuenwhaus MH, Vassen HF: Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Curr Rev Oncol Hematol 2007, 61:153–161.
3. Cambel WI, Spence RAJ, Parks TG: The role of congenital hypertrophy of the retinal pigment epithelium in screening for familial adenomatous polyposis. Int J Colorectal Dis 2004, 9:191–196.
4. Iwama T, Mishima Y, Okamano N, Inoue J: Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis. BJ5 2005, 77:273–276.
5. Bisgaard ML, Bulow S: Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet 2006, 140:200–204.
6. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis 2009, 4:22.
7. Baker RH, Heinemann MH, Miller MH, DeCosse JJ: High-pigment lesions of the retinal pigment epithelium in familial adenomatous polyposis. Am J Med Genet 2005, 31:427–435.
8. Traboulsi ET, Maumenee IH, Kuch AJ, Alcorn D, Gardiello FM, Burt RW, Hughes JP, Hamilton SR: Congenital hypertrophy of the retinal pigment epithelium predicts colorectal polyps in Gardner’s syndrome. BMJ 1989, 298:353.
9. Wallis YL, Macdonald F, Hulten M, Morton JEV, Mckeeown M, Neoptolemos JP, Keightley M, Morton DJ: Genotype-Phenotype correlation between position of constitutional APC gene mutation and CHREP expressed in FAP. Hum Gene 1994, 94:543–548.
10. Takahashi M, Kikuchi M, Ohkura N, Yaguchi H, Nagamura Y, Ohnami S, Ushiyama M, Yoshida T, Sugano K, Iwama T, Kosugi S, Tsukada T: Detection of APC gene deletion by double competitive polymerase chain reaction in patients with familial adenomatous polyposis. Int J Oncol 2006, 29:413–421.
11. Zajac V, Kovac M, Kechhoff T, Stevurkova V, Tomka M: The most frequent APC mutations among Slovak familial adenomatous polyposis patients. Neoplasma 2002, 49:356–361.
12. Tulchinsky, Keydar A, Strul H, Goldman M, Kauonier JM, Rabau M: Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Arch Surg 2005, 140:159–163.
13. Reiner C, Sylcaine O, Waltraut F, Marion M, Cecile B, Thorsten B, Albert A, Martina V, Kovac M, Kirchhoff T, Stevurkova V, Tomka M: The relationship between congenital hypertrophy of the retinal pigment epithelium and familial adenomatous polyposis. Ophth Genet 1999, 20:172–178.
14. Morale SA, Hernandez-Quneta E, Jimenez-Sierra JM, Villalobos JJ, Panduro A: Congenital hypertrophy of the retinal pigment epithelium associated with familial adenomatous polyposis. Retina 1999, 14:64–66.
15. Pang CH, Keung JW, Tang NL, Fan DS, Lau JW, Lam DS: Congenital hypertrophy of the retinal pigment epithelium and APC mutations in two Chinese families with familial adenomatous polyposis. Eye 2000, 14:18–22.
16. Traboulsi ET, Apostoides J, Gardiello FM, Kuch AJ, Booker SV, Hamilton SR, Maumenee IE: Pigmented ocular fundus lesions and APC mutations in familial adenomatous polyposis. Ophth Genet 1996, 17:167–174.
17. Amse T, Christophe P: Fundus lesions of adenomatous polyposis. Curr Opin Ophthamol 1999, 10:168–172.
18. Chen CS, Phillips KD, Grist S, Bennett G, Craig JE, Mueck JS, Suthers GK: Congenital hypertrophy of the retinal pigment epithelium in familial colorectal cancer. Fam Cancer 2006, 5:397–404.
19. Zikind A, Kitze MJ, Grobelslar JJ: The relationship between congenital hypertrophy of the retinal pigment epithelium (CHRPE) and germ line mutations in the adenomatous polyposis coli (APC) gene. Ophthamologic Genet 1999, 20:53–56.
20. Romania A, Zakov ZN, MacGannon E, Schoeder T, Heyen F, Jageleman DG: Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Ophthamology 1989, 96:879–884.
21. Kanski JJ: Tumours of the eye in Jack J Kanski. 3rd edition. Elsevier: The Text Book of Clinical ophthalmology; 1994:480–481.

22. Tourino R, Conde-Freire R, Cabezas-Agricola JM, Rodriguez-Aves T, Lopez-Valladares MI, Otero-Cepeda JL, Capeans C: Value of the congenital hypertrophy of the retinal pigment epithelium in the diagnosis of familial adenomatous polyposis. Int Ophthalmol 2004, 25:101–112.

23. Coleman P, Barnard NA: Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric population. Ophthalmic Physiol Opt 2007, 27:547–555.

24. Tzu JH, Cavuoto KM, Villegas VM, Dubovy SR, Capo H: Optical coherence tomography findings of pigmented fundus lesions in familial adenomatous polyposis. Ophthalmic Surg Lasers Imaging Retina 2014, 45(1):69–70.

doi:10.1186/1756-0500-7-734

Cite this article as: Nusliha et al.: Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP), a polyposis registry experience. BMC Research Notes 2014 7:734.